Cell Source, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CLCS research report →
Price Chart
About the company
Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based therapies centered on regulating immune tolerance. The company's flagship innovation is its Veto Cell immune system management technology, an advanced immune tolerance platform capable of selectively suppressing specific immune responses.
- CEO
- Itamar Shimrat
- IPO
- 2014
- Employees
- 1
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on CLCS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $37.05M
- P/E
- -5.45
- PEG
- -1.02
- P/S
- 0.00
- P/B
- -1.32
- EV/EBITDA
- -18.19
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 22.48%
- ROIC
- 28.75%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-2,725,665
- Net Income
- $-4,638,079+2.8%
- EPS
- $-0.10+33.3%
- OCF Growth
- -1.8%
- FCF Growth
- -1.8%
- 52W High
- $2.25
- 52W Low
- $0.25
- 50D MA
- $0.61
- 200D MA
- $0.76
- Beta
- -157.98
- RSI (14)
- 52
- Avg Volume
- 2.65K
No earnings-call transcripts are available for CLCS yet.
- Free Float
- 80.3%
- Shares Outstanding
- 67.95M
- Float Shares
- 54.53M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 10, 22 | Verstraete George | other | 0 |
| Aug 9, 21 | Soave Darlene | other | 800,000 |
| Jun 30, 21 | ZOLTY DAVID | other | 4,860 |
| Jun 30, 21 | Soave Darlene | other | 59,507 |
| Jun 30, 21 | Brown Dennis M | other | 2,976 |
| Jun 30, 21 | FRIEDMAN BENZION ABRAHAM | other | 19,440 |
| Dec 29, 20 | ZOLTY DAVID | other | 4,941 |
| Jun 30, 20 | ZOLTY DAVID | other | 4,887 |
| Dec 31, 19 | ZOLTY DAVID | other | 6,420 |
| Jun 26, 19 | ZOLTY DAVID | other | 1,339 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CLCS coverage
Recent articles, reports, and earnings notes.
No research on CLCS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CLCS report →Cell Source Presented Its Breakthrough Developments for Mismatched Donor Stem Cell and Organ Transplants and Off-the-shelf CAR-T Cell Therapy at the LD Micro Invitational Conference in Los Angeles This Week
accessnewswire.com · May 21
Cell Source, Inc. to Present at the LD Micro Invitational XVI
newsfilecorp.com · May 14
Cell Source Announces Closing of Private Placement and Hiring of Transfer Agent
accessnewswire.com · Jan 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.